Cited by 144Lung Cancer Treatments and MutationsPharmacogenetics and Drug MetabolismSmoking Behavior and Cessation

The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

Open access

Hughes, Andrew N., O'Brien, Mary E.R., Petty, W. Jeffrey, Chick, Jonathan B., Rankin, Elaine, Woll, Penella J., Dunlop, David, Nicolson, Marianne, Boinpally, Ramesh, Wolf, Julie, Price, Allan·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2008.19.3995PMC PMC2667823

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Cigarette smoking induces CYP1A1/1A2 and is hypothesized to alter erlotinib pharmacokinetics. This study aimed to determine the maximum tolerated dose (MTD) of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients who smoke and compare the pharmacokinetics of erlotinib at the MTD in current smokers with 150 mg. PATIENTS AND METHODS: Cohorts of NSCLC patients currently smoking > or = 10 cigarettes per day for > or = 1 year received escalating doses of erlotinib for 14 days until dose-limiting toxicity (DLT). A separate cohort of patients was then randomly assigned to erlotinib at either MTD or 150 mg daily with pharmacokinetics assessed at day 14. Erlotinib was continued until progression or intolerable toxicity. RESULTS: Four dose levels were evaluated in 22 patients: 200, 250, 300, and 350 mg. DLT was observed in one of six patients at 300 mg (rash) and two of five patients at 350 mg (acneiform dermatitis and fatigue/decreased Eastern Cooperative Oncology Group performance status). Thirty-five patients were randomly assigned to 150 mg or 300 mg. Common adverse events (all grades) were: skin toxicity (150 mg, 29%; 300 mg, 67%), diarrhea (150 mg, 18%; 300 mg, 50%), and fatigue (150 mg, 12%; 300 mg, 17%). Erlotinib exposure was dose-proportional within dose range tested. Median steady-state trough erlotinib plasma concentrations were 0.375 and 1.22 microg/mL for 150 mg and 300 mg, respectively. CONCLUSION: The MTD of erlotinib in NSCLC patients who smoke was 300 mg. Steady-state trough plasma concentrations and incidence of rash and diarrhea in smokers at 300 mg were similar to those in former or never smokers receiving 150 mg in previous studies. The potential benefit of higher erlotinib doses in current smokers warrants further evaluation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2008.19.3995

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Drug Interactions with Tobacco Smoking
Zevin, S., & Benowitz, N. L. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00004 · Cited by 711
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
Sequist, L. V. D., Bell, D. W., Lynch, T. J., & Haber, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3585 · Cited by 625
KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
Massarelli, E., Varella‐Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. D., Bekele, B. N., Herbst, R. S., & Wistuba, I. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3043 · Cited by 594
Effects of smoking on the pharmacokinetics of erlotinib
Hamilton, M., Wolf, J. L., Rusk, J., Beard, S. E., Clark, G. M., Witt, K., & Cagnoni, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2235 · Cited by 312
Self-citation
Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes
Li, J., Zhao, M., He, P., Hidalgo, M. M., & Baker, S. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0088 · Cited by 310
Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Bezjak, A., Tu, D., Seymour, L., Clark, G. M., Trajković, A., Zukin, M., Ayoub, J., Lago, S., Ribeiro, R. D. A., Gerogianni, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8073 · Cited by 295
Improved Survival in Never-Smokers vs Current Smokers With Primary Adenocarcinoma of the Lung
Nordquist, L. T., Simon, G. R., Cantor, A. B., Alberts, W. M., & Bepler, G. (2004) · CHEST Journal · doi:10.1378/chest.126.2.347 · Cited by 228

Show all 20 references

Research works printed but not linked: 1

Hamilton M, 2005, Proc Am Assoc Cancer Res, 46, 1451

Sorted by citations

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K. M., & Felip, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds226 · Cited by 940
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Reck, M., Popat, S., Reinmuth, N., Ruysscher, D. D., Kerr, K. M., & Peters, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu199 · Cited by 688
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 577
Clinical pharmacokinetics of tyrosine kinase inhibitors
van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503
Impact of Specific Epidermal Growth Factor Receptor ( EGFR ) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR -Mutant Lung Cancer: A Meta-Analysis
Lee, C. K., Wu, Y.-L., Ding, P. N., Lord, S. J., Inoue, A., Zhou, C., Mitsudomi, T., Rosell, R., Pavlakis, N., Links, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1736 · Cited by 327
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Janne, P. A., Gray, N. S., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 312
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 296
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q. C., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 309
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J. (2009) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 270
Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
Roberts, P. J., Stinchcombe, T. E., Der, C. J., & Socinski, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4365 · Cited by 245
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
Gion, P. D., Kanefendt, F., Lindauer, A., Scheffler, M., Doroshyenko, O., Fuhr, U., Wolf, J., & Jaehde, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11593320-000000000-00000 · Cited by 224
Self-citation
Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
Martins, R. G., Parvathaneni, U., Bauman, J. E., Sharma, A. K., Raez, L. E., Papagikos, M. A., Yunus, F., Kurland, B. F., Eaton, K. D., Liao, J. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3299 · Cited by 205
Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit
Jimenez-Ruiz, C. A., Andreas, S., Lewis, K. E., Tønnesen, P., van Schayck, O. C. P., Hájek, P., Tonstad, S., Dautzenberg, B., Fletcher, M. J., Masefield, S. C., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00092614 · Cited by 195
Determining the optimal dose in the development of anticancer agents
Mathijssen, R. H. J., Sparreboom, A., & Verweij, J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.40 · Cited by 184
EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy
Freudlsperger, C., Burnett, J. R., Friedman, J., Kannabiran, V. R., Chen, Z., & Waes, C. V. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.541440 · Cited by 183
Smoking Cessation: An Integral Part of Lung Cancer Treatment
Cataldo, J. K., Dubey, S., & Prochaska, J. J. (2010) · Oncology · doi:10.1159/000319937 · Cited by 181
Clinicopathologic Features of Advanced Squamous NSCLC
Socinski, M. A., Obasaju, C. K., Gandara, D. R., Hirsch, F. R., Bonomi, P., Bunn, P. A., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.024 · Cited by 186
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
Lee, S. M., Khan, I., Upadhyay, S., Lewanski, C. R., Falk, S. J., Skailes, G., Marshall, E., Woll, P. J., Hatton, M. Q. F., Lal, R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70412-6 · Cited by 179
Self-citation
Tobacco smoking after diagnosis of cancer: clinical aspects
Jassem, J. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.01 · Cited by 168
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Duruisseaux, M., Besse, B., Cadranel, J. L., Pérol, M., Mennecier, B., Bigay-Game, L., Descourt, R., Dansin, É., Audigier-Valette, C., Moreau, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15746 · Cited by 162
Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions
Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155
Effects of Cigarette Smoking on Metabolism and Effectiveness of Systemic Therapy for Lung Cancer
O'Malley, M. W., King, A. N., Conte, M. L., Ellingrod, V. L., & Ramnath, N. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000191 · Cited by 139
Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)
Reungwetwattana, T., Weroha, S. J., & Molina, J. R. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.004 · Cited by 127
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
Solassol, I., Pinguet, F., & Quantin, X. (2019) · Biomolecules · doi:10.3390/biom9110668 · Cited by 129
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
Scheffler, M., Gion, P. D., Doroshyenko, O., Wolf, J., & Fuhr, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587020-000000000-00000 · Cited by 110
Self-citation
Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care
Lankheet, N. A. G., Knapen, L. M., Schellens, J. H. M., Beijnen, J. H., Steeghs, N., & Huitema, A. D. R. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000004 · Cited by 109
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
Razak, A. R. A., Soulières, D., Laurie, S. A., Hotte, S. J., Singh, S., Winquist, E., Chia, S., Tourneau, C. L., Nguyen‐Tan, P. F., Chen, E. X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds503 · Cited by 104
Synthetic Pot: Not Your Grandfather’s Marijuana
Ford, B. M., Tai, S., Fantegrossi, W. E., & Prather, P. L. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.003 · Cited by 112
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
Josephs, D. H., Fisher, D. S., Spicer, J. F., & Flanagan, R. J. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318292b931 · Cited by 88
Effects of Tobacco Smoking and Nicotine on Cancer Treatment
Petros, W. P., Younis, I. R., Ford, J. N., & Weed, S. A. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01117 · Cited by 88
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 83
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
Thomas, F., Rochaix, P., White‐Koning, M., Hennebelle, I., Sarini, J., Benlyazid, A., Malard, L., Lefebvre, J., Chatelut, É., & Delord, J. P. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.007 · Cited by 81
Clinical Significance of Smoking Cessation in Subjects With Cancer: A 30-Year Review
Florou, A., Gkiozos, I., Tsagouli, S. K., Souliotis, K. N., & Syrigos, K. N. (2014) · Respiratory Care · doi:10.4187/respcare.02559 · Cited by 78
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
Balagula, Y., Garbe, C., Myskowski, P. L., Hauschild, A., Rapoport, B. L., Boers-Doets, C. B., & Lacouture, M. E. (2011) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04791.x · Cited by 71
Selective Inhibition of Human Solute Carrier Transporters by Multikinase Inhibitors
Johnston, R. A., Rawling, T., Chan, T., Zhou, F., & Murray, M. T. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059097 · Cited by 70
Impact of Smoking on Lung Cancer Treatment Effectiveness: A Review
Condoluci, A., Mazzara, C., Zoccoli, A., Pezzuto, A., & Tonini, G. (2016) · Future Oncology · doi:10.2217/fon-2015-0055 · Cited by 64
Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
Xu, Z., & Li, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s194870 · Cited by 60
The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials
Hasegawa, Y., Ando, M., Maemondo, M., Yamamoto, S., Isa, S., Saka, H., Kubo, A., Kawaguchi, T., Takada, M., Rosell, R., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0285 · Cited by 57
The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study
Danson, S. J., Rowland, C., Rowe, R., Ellis, S. P., Crabtree, C., Horsman, J. M., Wadsley, J., Hatton, M. Q. F., Woll, P. J., & Eiser, C. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2928-x · Cited by 53
Self-citation
Structures of human cytochrome P450 1A1 with bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands
Bart, A. G., & Scott, E. E. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005588 · Cited by 50
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)
Tiseo, M., Andreoli, R., Gelsomino, F., Mozzoni, P., Azzoni, C., Bartolotti, M., Bortesi, B., Goldoni, M., Silini, E. M., Palma, G. D., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.12.001 · Cited by 45
Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?
LoRusso, P. M., Boerner, S. A., & Hunsberger, S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1311 · Cited by 43
Erlotinib
Petit-Jean, E., Buclin, T., Guidi, M., Quoix, É., Gourieux, B., Decosterd, L. A., Gairard-Dory, A., Ubeaud-Séquier, G., & Widmer, N. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000097 · Cited by 43
It’s never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival
Roach, M. C., Rehman, S. S. U., DeWees, T. A., Abraham, C. D., Bradley, J. D., & Robinson, C. G. (2015) · Practical Radiation Oncology · doi:10.1016/j.prro.2015.09.005 · Cited by 41
Evolution of systemic therapy for advanced pancreatic cancer
Renouf, D. J., & Moore, M. J. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.21 · Cited by 41
Benefit of Erlotinib in Patients with Non-Small-Cell Lung Cancer Is Related to Smoking Status, Gender, Skin Rash and Radiological Response but Not to Histology and Treatment Line
Faehling, M., Eckert, R., Kuom, S., Kamp, T., Stoiber, K., & Schumann, C. (2010) · Oncology · doi:10.1159/000315731 · Cited by 40
Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry
Harada, T., López-Chávez, A., Xi, L., Raffeld, M. A., Wang, Y., & Giaccone, G. (2010) · Oncogene · doi:10.1038/onc.2010.545 · Cited by 37
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
Gridelli, C., Maione, P., Bareschino, M. A., Schettino, C., Sacco, P. C., Ambrosio, R., Barbato, V., Falanga, M., & Rossi, A. (2010) · PubMed · Cited by 38
Optimizing the Management of Advanced Non-small-Cell Lung Cancer: A Personal View
Vincent, M. D. (2009) · Current Oncology · doi:10.3747/co.v16i4.465 · Cited by 36
Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer
Piperdi, B., & Perez-Soler, R. (2012) · Drugs · doi:10.2165/1163018-s0-000000000-00000 · Cited by 38
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin
Ranson, M., Shaw, H. M., Wolf, J., Hamilton, M., McCarthy, S. P., Dean, E. J., Reid, A. H. M., & Judson, I. R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1133-3 · Cited by 35
Self-citation
Smoking Cessation in Lung Cancer
Andreas, S., Rittmeyer, A., Hinterthaner, M., & Huber, R. M. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0719 · Cited by 35
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’
Boeck, S. H., Vehling‐Kaiser, U., Waldschmidt, D., Kettner, E., Märten, A., Winkelmann, C., Klein, S., Kojouharoff, G., Gauler, T. C., von Weikersthal, L. F., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833123ed · Cited by 34
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
Renouf, D. J., Tang, P. A., Hedley, D. W., Chen, E., Kamel‐Reid, S., Tsao, M., Tran‐Thanh, D., Gill, S., Dhani, N. C., Au, H., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.008 · Cited by 31
Smoking History as a Predictive Factor of Treatment Response in Advanced Non–Small-Cell Lung Cancer: A Systematic Review
Mitchell, P. L. R., Mok, T. S. K., Barraclough, H., Strizek, A., Lew, R. A., & Kooten, M. V. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.003 · Cited by 31
Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents
Duong, S., & Leung, M. (2010) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155210381794 · Cited by 30
Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy
MacLeod, A. K., Lin, D., Huang, J. T.-J., McLaughlin, L. A., Henderson, C. J., & Wolf, C. R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3555 · Cited by 29
Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers
Kolesar, J., Peh, K. H., Thomas, L., Baburaj, G., Mukherjee, N., Kantamneni, R., Lewis, S. C., Pai, A., Udupa, K., Kumar, N. A. N., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01534-8 · Cited by 32
The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis
Li, X., Huang, C., Xie, X., Wu, Z., Tian, X., Wu, Y., Du, X., & Shi, L. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13309 · Cited by 28
Association of ABCB1 Polymorphisms with Erlotinib Pharmacokinetics and Toxicity in Japanese Patients with Non-Small-Cell Lung Cancer
Hamada, A., Sasaki, J.-I., Saeki, S., Iwamoto, N., Inaba, M., Ushijima, S., Urata, M., Kishi, H., Fujii, S., Semba, H., et al. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.176 · Cited by 27
Effects of continued tobacco use during treatment of lung cancer
Waller, L. L., Weaver, K. E., Petty, W. J., & Miller, A. A. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.140 · Cited by 27
Self-citation
The ability of polycyclic aromatic hydrocarbons to alter physiological factors underlying drug disposition
Elsherbiny, M. E., & Brocks, D. R. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.596204 · Cited by 26
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
O’Bryant, C. L., Haluska, P., Rosen, L. S., Ramanathan, R. K., Venugopal, B., Leong, S., Boinpally, R., Franke, A., Witt, K., Evans, J., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1733-6 · Cited by 25
Self-citation
Cigarette Smoking and Gemcitabine-Induced Neutropenia in Advanced Solid Tumors
O'Malley, M. W., Healy, P. N., Daignault, S. D., & Ramnath, N. (2013) · Oncology · doi:10.1159/000355107 · Cited by 25
Management strategies in pancreatic cancer
Campen, C. J., Dragovich, T., & Baker, A. F. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100254 · Cited by 24
Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer
Pillai, V. C., Venkataramanan, R., Parise, R. A., Christner, S. M., Gramignoli, R., Strom, S. C., Rudek, M. A., & Beumer, J. H. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052100 · Cited by 24
Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events
Sibbald, M., Yan, A. T.-K., Huang, W., Fox, K. A. A., Gore, J. M., Steg, P. G., Eagle, K. A., Brieger, D. B., Montalescot, G., & Goodman, S. G. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.026 · Cited by 23
Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug–drug interaction
Das, M. S., Padda, S. K., Frymoyer, A. R., Zhou, L. Y., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.011 · Cited by 23
Concentrations of Erlotinib in Tumor Tissue and Plasma in Non–Small-Cell Lung Cancer Patients After Neoadjuvant Therapy
Lankheet, N. A. G., Schaake, E. E., Burgers, S. A., van Pel, R., Beijnen, J. H., Huitema, A. D. R., & Klomp, H. M. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.012 · Cited by 23
A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer
McGranahan, T. M., & Nagpal, S. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0466-0 · Cited by 21
Safety profile of new anticancer drugs
Mansi, L., Thiery-Vuillemin, A., Nguyen, T., Bazán, F., Calcagno, F., Rocquain, J., Demarchi, M., Villanueva, C., Maurina, T., & Pivot, X. B. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740330903530663 · Cited by 20
Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses
Phelps, M. A., Stinchcombe, T. E., Blachly, J. S., Zhao, W., Schaaf, L. J., Starrett, S. L., Wei, L., Poi, M. J., Wang, D., Papp, A., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.93 · Cited by 21
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Becker, K. D. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.560 · Cited by 19
Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use
Gougis, P., Palmieri, L., Funck‐Brentano, C., Paci, A., Flippot, R., Mir, O., & Coriat, R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.006 · Cited by 21
Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke
Waller, L. L., Miller, A. A., & Petty, W. J. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.08.014 · Cited by 16
Self-citation
Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes
Song, X., Varker, H., Eichelbaum, M. F., Stopfer, P., Shahidi, M., Wilson, K. L., Kaiser, R., & Finnern, H. W. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.016 · Cited by 15
Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay
Yamamoto, Y., Saita, T., Yamamoto, Y. L., & Shin, M. (2018) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2017.10.002 · Cited by 15
Pharmacokinetic Properties of Two Erlotinib 150 mg Formulations with a Genetic Effect Evaluation in Healthy Korean Subjects
Choi, H.-G., Jeon, J., Im, Y., Kim, Y., Song, E., Seo, Y.-H., Cho, S.-J., & Kim, M. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0248-4 · Cited by 14
“Stop Smoking!” Do We Say It Enough?
Hildebrand, J. R., & Sastry, S. (2013) · Journal of Oncology Practice · doi:10.1200/jop.2013.000890 · Cited by 14
Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
Faehling, M., Achenbach, J., Staib, P., Steffen, U., Tessen, H. W., Gaillard, V. E., & Brugger, W. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2649-x · Cited by 16
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)
Smit, E. F., Wu, Y.-L. L. C., Gervais, R., Zhou, C., Felip, E., Feng, J., Güçlü, S. Z., Hoiczyk, M., Dorokhova, E., Freudensprung, U., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.019 · Cited by 13
Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents
Visentin, M., Biason, P., & Toffoli, G. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.05.005 · Cited by 13
Thienopyridine efficacy and cigarette smoking status
Bliden, K. P., Baker, B., Nolin, T. D., Jeong, Y., Bailey, W. L., Tantry, U. S., & Gurbel, P. A. (2013) · American Heart Journal · doi:10.1016/j.ahj.2012.12.024 · Cited by 12
High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer
Petty, W. J., Voelzke, W. R., Urbanic, J. J., Varela, V. A., Waller, L. L., Swift, C. B., Graham, R. M., Memoli, V. A., & Dragnev, K. H. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.04.004 · Cited by 12
Self-citation
Epidermal Growth Factor Receptor Pathway
Bonomi, P. (2010) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000391370.86753.90 · Cited by 12
Drug Exposure: Still an Excellent Biomarker
Meza–Junco, J., & Sawyer, M. B. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.58 · Cited by 11
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
Kumar, R., Lu, S. K., Minchom, A. R., Sharp, A., Davidson, M., Gunapala, R., Yap, T. A., Bhosle, J., Popat, S., & O'Brien, M. E. R. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2950-1 · Cited by 10
Self-citation
Moving Towards Molecular-Guided Treatments: Erlotinib and Clinical Outcomes in Non-Small-Cell Lung Cancer Patients
Santarpía, M., Pas, T. M. D., Altavilla, G., Spaggiari, L., & Rosell, R. (2013) · Future Oncology · doi:10.2217/fon.13.6 · Cited by 11
Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer
Yamamoto, Y., Iida, S., Kawanishi, T., & Fukuoka, M. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12232 · Cited by 10
Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions
Chen, H. X., Cleck, J. N., Coelho, R. P., & Dancey, J. E. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.10.002 · Cited by 10
Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial
Gomez‐Mancilla, B., Dürsteler, K. M., Vogel, M., Herdener, M., Torrens, M., Gálvez, B. P., Gual, A., Corral, R. M., Kuper, E., Mosca, D., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adi4505 · Cited by 10
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations
Suzuki, H., Hirashima, T., Okamoto, N., Yamadori, T., Tamiya, M., Morishita, N., Shiroyama, T., Otsuka, T., Kitai, K., & Kawase, I. (2012) · 癌症：英文版 · doi:10.5732/cjc.012.10160 · Cited by 7
Former smokers with non‐small‐cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis
Zheng, S., Wang, R., Zhang, Y., Pan, Y., Cheng, C., Zheng, D., Sun, Y., & Chen, H. (2016) · Cancer Medicine · doi:10.1002/cam4.764 · Cited by 7
Late phase 1 studies: concepts and outcomes
Benítez, J. C., Géraud, A., Texier, M., Massard, C., Paci, A., Soria, J., & Besse, B. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00467-8 · Cited by 9
Smoking Cessation with Lung Cancer: Not Too Little, Never Too Late!
Gemine, R. E., & Lewis, K. E. (2016) · EMJ Respiratory · doi:10.33590/emjrespir/10311510 · Cited by 7
Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor–Mutated Non-Small Cell Lung Cancer Patients
Liao, D., Liu, Z., Zhang, Y., Liu, G., Yao, D., Cao, L., Chen, Y., Fu, Y., Yang, N., & Xiang, D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00664 · Cited by 7
Le tabac et ses conséquences dans le cadre du traitement du cancer bronchique
Rivera, C., Rivera, S., Fabre, E., Pricopi, C., Pimpec‐Barthes, F. L., & Riquet, M. (2015) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2014.11.009 · Cited by 6
Rapid onset of conjunctivitis associated with overdosing of erlotinib
Sun, P., Long, J., Chen, P., He, Q., Gao, X., & Li, S. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12641 · Cited by 7

Authors: Hughes, A. N., O'Brien, M. E. R., Petty, W. J., Chick, J. B., Rankin, E., Woll, P. J., Dunlop, D., Nicolson, M., Boinpally, R., Wolf, J., & Price, A.
Affiliations: Aberdeen Royal Infirmary (GB)
ORCID: Hughes, Andrew N.
O'Brien, Mary E.R.
Petty, W. Jeffrey
Woll, Penella J.
Dunlop, David
Boinpally, Ramesh
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-03-10
Volume: 27
Issue: 8
Pages: 1220-1226
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2008.19.3995
PMC: PMC2667823
OpenAlex: W2140617449
Cited by: 144
References: 20
Citations by year: 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 8 · 2018: 7 · 2017: 5 · 2016: 8 · 2015: 11 · 2014: 15 · 2013: 19 · 2012: 9
FWCI: 15.44
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Discovery Research Portal (University of Dundee) (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Keywords: erlotinib, cigarette smoking, non-small cell lung cancer, maximum tolerated dose, pharmacokinetics, dose-limiting toxicity, rash, diarrhea, dose escalation, drug metabolism
MeSH terms: Erlotinib Hydrochloride, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Quinazolines, Smoking, Cytochrome P-450 CYP1A1, Cytochrome P-450 CYP1A2, Maximum Tolerated Dose, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks